Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Birgitte Rasmussen(Nordsjællands Hospital), Meredith M. Regan(Dana-Farber Cancer Institute), Anne E. Lykkesfeldt(Danish Cancer Society), Patrizia Dell’Orto(European Institute of Oncology), Barbara Del Curto(European Institute of Oncology), Katrine L. Henriksen(Danish Cancer Society), Mauro G. Mastropasqua(European Institute of Oncology), Karen N. Price(Dana-Farber/Harvard Cancer Center), Eliane Mery-Lamarche(Institut Claudius Regaud), Magali Lacroix‐Triki(Institut Claudius Regaud), Stephen Braye(Clinical Trials New Zealand), Hans J. Altermatt(Oncosuisse), Richard D. Gelber(Dana-Farber Cancer Institute), Monica Castiglione‐Gertsch(International Breast Cancer Study Group), Aron Goldhirsch(Institute of Oncology Research), Barry A. Gusterson(Western Infirmary), Beat Thürlimann(Swiss Group For Clinical Cancer Research), Alan S. Coates(International Breast Cancer Study Group), Giuseppe Viale(University of Milan)
Cited by 151
Abstract
Related Papers
No related papers found
Powered by citation graph analysis